Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would just be happy to see us come off the greys and trade again! .25 cents for starters would be really nice! :))
Who are the people in our neighborhood? We've seen recent beneficial ownership documents filed for both Baudax and Gracell. I can't wait to see how this helps Humanigen leverage our position with Tera-Immune and with CAR-T enhancement. We've got documented evidence of our interest in both companies.
But I'm most excited to see how a relationship may develop between Humanigen and Novavax, even though I have seen no evidence to believe that a specific relationship is being developed. I base my suspicion on our patented lenz/vaccine cocktail, and on what I perceive as unmet needs that the two companies can provide for each other. I'm super-excited at the prospect of a partnership being announced. And we have seen several beneficial ownership documents filed recently for Novavax, as well.
D***,
"D ⭐️⭐️⭐️
@_flyers77
What are the different options of how this can play out?"
What are the different options of how this can play out?
— D (@_flyers77) February 11, 2024
"February 12, 2024 at 4:00 p.m. (Eastern): Deadline to submit Bid to be considered for the Auction.
February 13, 2024 at 4:00 p.m.: Sale Objection Deadline
February 13, 2024 at 10:00 a.m.: Auction (if necessary)
see pg 10/95
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1056710&projectCode=HUM&docketNumber=64&source=DM
Tomorrow could be a pivotal day for us. I hope things go as I expect, and that we may see additional news, as well. I think management has executed superbly.
Morgan Stanley today announced the acquisition of 7,281,646 shares of Novavax (6.2% stake).
https://www.sec.gov/Archives/edgar/data/1000694/000089542124000158/0000895421-24-000158-index.htm
Third beneficial ownership filing in about 5 weeks (State Street/SSGA and Blackrock).
https://www.sec.gov/Archives/edgar/data/1000694/000089542124000158/0000895421-24-000158-index.htm
Novavax has almost the same OS that Humanigen has, (Shares Outstanding 118.79M) and they are now trading at a 52 week low. I would love to see a stock-for-stock business combination or partnership with them. Huge potential. Look at their 5 year chart.
https://ih.advfn.com/stock-market/NASDAQ/novavax-NVAX/chart/real-time
Even if they only used the lenz vaccine cocktail for immuno-compromised and elderly patients, and even if that only popped our Market Cap to $8B, that could still be a sustained annual revenue of $67 per share for Humanigen.
Yes, I have a recognized, long-standing, pro-bias opinion toward Novavax. But we developed our patent for a reason, and this is the ideal application for that patent.
"METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY
Publication number: 20230109208
Abstract: The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.
Type: Application
Filed: March 8, 2021
Publication date: April 6, 2023
Applicant: HUMANIGEN, INC.
Inventors: Cameron DURRANT, Dale CHAPPELL
https://patents.justia.com/assignee/humanigen-inc
😁 🙂 That is where Jay's $200 per share comes in.
So what happens if those shares are unavailable to be bought back? :))
I think the float of 192% of our OS came from our Transfer Agent to the Nasdaq Appeals Hearing committee, at their request. And yes, those shares will have to be bought-in during the recall of our loaned shares. I think Humanigen controls 110M of the 119M shares in our OS (92% of the shares controlled by the company, versus 70% of the shares the company owned in the previous recall of our loaned shares). This is my opinion along with why I came to this conclusion.
Wow that is significantly higher than the reported OS. So those shared will have to be recalled then. Wow!
Not to mention any shares that were shorted for example when I bought my shares and they were basically given to me for nothing.
It's going to be fun watching the short squeeze take place here when this begins to trade again.
I go back to the reported float of 229M shares, which is >192% of our OS, and which I think Humanigen has control of 110M of those shares.
Our OS is only around 119 million shares. How many loaned shares are out there? If they are forced to return these shares we could see an incredible short squeeze here. I got quite a few shares locked down myself.
The only thing I want more than that is the recall of our loaned shares. But I want both the recall and the relisting as the profitable company we are about to become.
I can't wait to get past chapter 11 so that we can move forward!
I think we are about to blaze new frontiers of safety and efficacy across treatments of multiple indications. CMML is probably the nearest horizon, and it has not only the prospect of an expedited regulatory approval, but also the promise of a Priority Review Voucher. And of course, the biggest impact could be in using lenz as both a covid therapeutic as well as with the Novavax vaccine. And I'm very curious to see if Durrant pursues using Ifab as an ADC for Glioblastoma before CytoDyn gets too far into their program for this indication. Also, Kite/Gilead continues to be a joke, with Gilead's magrolimab failure, and Kite touting a reduction in processing time from16 days, down to 14 days, for their CAR-T, which compares to 24 hours for Gracell's new processing time. And the Class Action lawyers faulted Humanigen for not recognizing magrolimab as a viable competitive product. Gilead abandoned their magrolimab trial for lack of efficacy. That's why I told eb that I was sick and tired of looking at the Class Action suit. Lead Counsel did more to harm shareholders than the $0.047 they have settled for (which only seems to apply for about 53% of our shares, anyway).
I really think Humanigen is stronger than it has ever been, and I remain super-excited about the recall of our loaned shares.
I wish I was as optimistic as that, but then again this is the first CH11 stock play I have seen since the EM tier and trading restrictions were put in place.
I have seen other CH11 plays make huge pps swings and volume during the CH11 process before EM, but this is new territory for me.
Fingers crossed here! My best trading and investing strategy so far haha!
When we reemerge from chapter 11 intact, and they file to get us listed again this thing could come out at a couple of bucks per share.
I am so Happy I own shares here!
I truly believe that this is going to have a "Happy Ending" and not the Massage Parlor type! LOL :))
"(January 8, 2024, 6:35 PM EST) -- Biopharmaceutical company Humanigen Inc. received bankruptcy court approval Monday to access half of a $2 million debtor-in-possession loan to help fund its ongoing drug development operations and its Chapter 11 case."
https://www.google.com/search?q=Humanigen+Gets+Access+To+New+Cash+For+Ch.+11+Process&oq=Humanigen+Gets+Access+To+New+Cash+For+Ch.+11+Process&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIGCAEQRRg80gEJNTYxM2owajE1qAIAsAIA&sourceid=chrome&ie=UTF-8#ip=1
This hasn't stopped the Official Committee of Unsecured Creditors of Humanigen from hiring Kilpatrick Townsend & Stockton as co-counsel.
https://www.wsj.com/articles/firm-retention-summary-humanigen-9994dd15?utm_source=dlvr.it&utm_medium=twitter
Seems to me that the DIP Lender, and the Unsecured Creditors, both see some value.
Even more, it makes me wonder what drug development Durrant has keyed-in on at this particular point in time. Is this to support our partners in the PREACH-M trial, or the RATinG trial? It's a very positive sign of Durrant's continuing faith in lenzilumab.
Or, is Durrant's interest in promoting Ifab as an ADC, as shown on slide 3 of our Featured Presentation?
https://ir.humanigen.com/English/events-and-presentations/default.aspx
After all, CytoDyn recently announced that Glioblastoma was being targeted as a treatment candidate with their partners.
Just noting that Intracoastal Capital filed a number of Amended 13G's yesterday, mainly for various biotech holdings, including Baudax. Intercoastal is exercising warrants for over 814K shares of Baudax.
I'm curious to see how this may factor into our interest in Tera-Immune, one week ahead of the Sale Hearing.
https://www.sec.gov/Archives/edgar/data/1646799/000121390024010366/ea192880-13ga1intra_baudax.htm
Time for our own "Extraordinary Measures."
I look at Dale's Appeal, and the Class Action Settlement, and Durrant's move to become both the stalking horse bidder as well as the DIP lender, as legal steps on our journey, which is also causing significant interest in Novavax, which I think will lead to covid market dominance for them in partnership with Humanigen. Time for management now to recall the loaned shares.
U need to get over deranged thoughts and LIES.
Get over it, Yooo. I'm excited abut what is going on here.
eb, I have just sent the following to the Project Manager at AB Data Ltd.
Re: [External]Exclusion from Litigation
Jay Booth
From:
jayatthelake2003@yahoo.com
To:
Ann Cavanaugh
Sat, Feb 3 at 6:15 PM
Dear Ms. Cavanaugh.
Your instruction that I must send a letter by mail, and that I must provide transaction details in Humanigen securities, to be excluded from litigation, impose requirements that I don't feel well enough to comply with. I will simply comply with page 2 of the Notice of Pendency:
"DO NOTHING Get no payment."
I strongly disagree with the Lead Counsel, as I have publicly declared in the following.
cowtown jay
Re: bencozey post# 41218
Tuesday, December 19, 2023 7:38:43 PM
Post#
41220
of 41817 Go
As the ACTIV-5 government-sponsored trial of lenzilumab was announced, I felt that it was nothing more than the commandeering of our successful LIVE-AIR trial results. A simple comparison of the trial designs prove that. Look at the patient inclusion criteria for the two trials.
The government-sponsored ACTIV-5 trial inclusion criteria #6:
"Illness of any duration, and requiring, just prior to randomization, supplemental oxygen (any flow), mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO) (ordinal score 5, 6, or 7)."
https://clinicaltrials.gov/study/NCT04583969?intr=Lenzilumab&rank=2
The company-sponsored LIVE-AIR trial inclusion criteria:
"SpO2 ≤ 94% on room air and/or require low-flow supplemental oxygen and/or require high-flow oxygen support or NIPPV
Hospitalized, not requiring invasive mechanical ventilation during this hospitalization"
https://clinicaltrials.gov/study/NCT04351152?intr=Lenzilumab&rank=3
The government excluded room air patients in their trial, and included patients on IMV and ECMO. Humanigen did not intend to treat patients that were as seriously ill as the government included in their trial.
And in case you haven't seen just how successful the LIVE-AIR trial results were, here are the peer reviews from Lancet and Thorax on this page.
Humanigen, Inc.
I've been here since 2017. I know the company hoped that ACTIV-5 would corroborate our findings. But including patients in such a late-stage of disease progression in their trial, and excluding the room air patients who did so well in the LIVE-AIR trial, only demonstrates that ACTIV-5 was never going to corroborate the LIVE-AIR trial results.
Lenzilumab is going to be a blockbuster drug (generate over $1B in yearly revenue). Pfizer needs that revenue. But we don't need Pfizer, or any other Big Pharma, to capture this market potential. Durrant has already run 5 blockbuster products through the FDA validation process. And Dale is a specialist in the field of T cell memory function, having been published in his post-doctoral work with the Howard Hughes Medical Institute.
I have shown you the proof of what this management team has done. And I have demonstrated the government's effort to safeguard the revenue of their Big Pharma sponsors. Hopefully, facts will persuade you that the NIH and the FDA are the real culprits here, with the deadly abuse of their discretionary authority."
Thank you,
Jay Booth
I just got that notice emailed to me overnight also.
The Sale Hearing is scheduled on Feb 14th at 1:30 Eastern. It remains a CH11 case. Humanigen has never been stronger than we are now. All we need is to stay the course on this transformation.
Simply delusional and unfair to rub salt in the wounds to all bag holders with these crazy theories and insane thoughts.
Don’t worry. Pfizer is going to buy us out at $150 a share. Just ask CJ.
Remember when other bio companies, such as Pfizer, initially reported the efficacy rates of their covid vaccines? Here's an example.
"Published online 2021 Dec 30
Development of an effective vaccine against Covid-19 is crucial to reducing infection. mRNA BNT162b2, developed and manufactured by Pfizer-BioNTech, was one of the first FDA-approved vaccinations reporting high efficacy (95%) and minimal side effects. Evaluating effectiveness of BNT162b2 in a general population has been made possible after the implementation of a nation-wide vaccination program in Israel...
BNT162b2 was found effective for the total population group for infection, hospitalization and mortality, with adjusted VE of 93·0% (CI:92·6–93·4%), 93·4% (CI:91·9–94·7%) and 91·1% (CI:86·5–94·1%) respectively."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717697/
We now know that wasn't true.
The latest iteration reports:
"Newest COVID shots are 54% effective in preventing symptoms, CDC finds
MIKE STOBBE
Thu, February 1, 2024
The latest versions of COVID-19 vaccines were 54% effective at preventing symptomatic infection in adults, according to the first U.S. study to assess how well the shots work."
https://www.yahoo.com/news/newest-covid-shots-54-effective-180123474.html
So in terms of preventing symptomatic infection, vaccines such as Pfizer's represent a coin toss in preventing symptomatic infection. And remember, there is no approved covid treatment authorized by the FDA for the majority of the US population.
After trillions of dollars in damage to the worldwide economies and health care systems, the best we can do is prevent symptomatic infections about half the time, and hope that we won't need a therapeutic treatment, because the FDA hasn't approved one, such as lenz.
I really hope that Humanigen and Novavax will change the covid prevention and treatment paradigm.
Walmart is having a sale today.. This is as relevant to HGENQ sharesholders as any other posts about other bio companies
Kite announces manufacturing process change to improve turnaround time for Yescarta CAR-T therapy. The improvement pales in comparison to what Gracell has demonstrated.
https://www.gilead.com/news-and-press/press-room/press-releases/2024/1/kite-receives-us-fda-approval-of-manufacturing-process-change-resulting-in-reduced-median-turnaround-time-for-yescarta-car-tcell-therapy
Good luck to CtyoDyn on the resubmission of their revised HIV clinical trial protocol to the FDA. They also announced that their partnership with Montefiore and Albert Einstein College plans to move forward with a pre-clinical trial designed to study leronlimab in glioblastoma, which is also an indication that Humanigen has studied for treatment. It's good to see researchers focus on immunomodulators as treatment therapeutics for these indications.
https://www.globenewswire.com/news-release/2024/02/01/2821970/19782/en/CytoDyn-Announces-Submission-of-Clinical-Protocol-to-FDA-and-Initiation-of-Pre-Clinical-Study-in-Glioblastoma.html
Definition of insanity
Wow! What great research! Thanks for sharing your dd. And thanks for bringing the ?newbie? up to speed on what is happening.
Here's something interesting, eb.
Humanigen published top line data (TLD) just after one year of initiating the LIVE-AIR trial.
https://ir.humanigen.com/English/news/news-details/2021/Humanigen-Reports-Positive-Phase-3Topline-Results-Demonstrating-That-Lenzilumab-Improves-Survival-Without-Need-for-Mechanical-Ventilation-in-Hospitalized-Patients-With-COVID-19/default.aspx
That was a wake up call that Pfizer and the PfDA faced the potential loss of billions in revenue, and in commercial support of FDA operations.
Prior to that, we had restructured from Kalobios to Humanigen, and also executed the recall of our loaned shares in November of 2015. But it wasn't until Humanigen proved their bona fides with the LIVE-AIR TLD that the SEC came to the FDA's defense.
Within months of Humanigen's TLD, the SEC filed charges against Murchinson (and indirectly against Dale, in my opinion) in August of 2021.
https://www.sec.gov/news/press-release/2021-156
"According to the SEC's order, from June 2016 through October 2017, the respondents provided erroneous order-marking information on hundreds of sale orders of their hedge fund client to the hedge fund's brokers, causing those brokers to mismark the hedge funds' sales as "long." The order finds that in providing the inaccurate information, the respondents also caused the hedge fund’s brokers to fail to borrow or locate shares prior to executing the sales. The order further finds that Murchinson and Bistricer caused the hedge fund to engage in dealer activity without registering with the SEC or being exempt from registration."
And the Admin Proceeding was filed as an SEC enforcement action, as usual.
https://www.sec.gov/files/litigation/admin/2021/34-92684.pdf
The charges were filed 5 years after the fact, and amount to bullshit. The SEC didn't dare to file an enforcement action as they should have. Instead, they filed a civil suit, which I only found out about when Agrippa posted an AI-generated notification in this regard.
"AgrippaAntinous
Jan 03, 2024 1:29 PM
$HGENQ interesting conversation with AI:
sec vs dale chappell et al and black horse. what is accusation
According to the web search results, the accusation is that Dale Chappell and his entities, Black Horse Capital LP, Black Horse Capital Master Fund Ltd, and Cheval Holdings Ltd, engaged in a fraudulent scheme to misappropriate millions of dollars from investors and manipulate the market for certain publicly traded securities12. The SEC filed a complaint against them in the U.S. District Court for the Eastern District of Pennsylvania on August 11, 2023, alleging violations of the antifraud provisions of the federal securities laws12. The case is currently pending in the U.S. Court of Appeals for the Third Circuit, where the defendants have appealed the district court’s order granting a preliminary injunction and freezing their assets13. The case is scheduled for oral argument on January 16, 2024."
https://stocktwits.com/AgrippaAntinous/message/556601076
I looked up the AI-generated reference.
"August 11, 2023 Opinion or Order Filing 1 APPLICATION AND ORDER FOR EXEMPTION FROM THE ELECTRONIC PUBLIC ACCESS FEES BY LI HUANG; THIS EXEMPTION IS VALID UNTIL 12/31/2023; THIS EXEMPTION MAY BE REVOKED AT THE DISCRETION OF THE COURT AT ANY TIME; A COPY OF THIS ORDER SHALL BE SENT TO PACER SERVICE CENTER. SIGNED BY CHIEF JUDGE JUAN R. SANCHEZ ON 8/11/23. 8/11/223 ENTERED & E-MAILED. COPY SENT TO PACER SERVICE CENTER. (fdc)"
https://dockets.justia.com/docket/pennsylvania/paedce/2:2023mc00115/612553
I noted that the petitioner, Li Huang (also spelled Liu Huang) apparently works for the NIH.
"Li Huang
Application and Data Manager at NIH/NICHD
Rockville, Maryland, United States Contact Info
74 followers 72 connections
https://www.linkedin.com/in/li-huang-ab95437
Dale's Appeal to the Third Circuit, which is largely sealed, was calendared for Jan 16th, and I see no change to that.
https://dockets.justia.com/docket/circuit-courts/ca3/23-2776
I think this Appeal is critical for us, since our assets were frozen.
I also think Dale prevailed in his Appeal, and that is why we see the disputes in the bankruptcy case have been worked out.
"TwongStocks
Jan 25, 2024 2:20 PM
$HGENQ Docket 64, 2nd revision to bid procedures.
document.epiq11.com/documen...
Seems the parties have worked out their issues. Per para 5, the US Trustee and UCC do not object to this revision. Taran does not consent or object. So as long as there are no more objections, the Court will likely finalize the bid procedures order."
https://stocktwits.com/TwongStocks/message/559238962
I remain highly confident that Humanigen will be able to initiate a new recall of their loaned shares. Management has not bowed to the superior firepower of the SEC, NIH, NIAID, and the FDA, and I look forward to our future.
HGENQ = BIOAQ = SPNGQ
Jay is nuts.
Jay has been telling us, and since your account is so new, you might have missed it......unless you really are someone else......multiple accounts/sceeen names.
The guys are going to take the company, and force all of you who are short, and especially you who are criminally naked short, and force you to return the shares you have "borrowed" or that you counterfeited. Simple as that. Jay and the rest of us suffering longs will be vindicated, paid for our investments.
That is our dream and it is the answer to your question that you have iterated so many times..(drop the mic)
Why would anyone make a bid for an asset that sates ZERO value on the balance sheet for it's intangible, intellectual property?
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’. Lenzilumab is a first-in class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF).
On the schedule of assets it's the value for it's intangible assets, intellectual property has a value of 0. on line 89
humanigen owns the ip for LENZ
LENZ® now available for
Lenzilumab is the only molecule asset it has and on the asset value they report the value as 0 since they cannot get FDA approval. it's value is 0.
Compassionate Use in the U.S. and via LenzMAP™ in the UK, select EU countries, and India
Another poster posting for the first time on a bankrupt stock that’s on the EM? Why do you care?
NOTICE OF BID PROCEDURES, AUCTION, HEARING,
AND DEADLINES RELATING TO THE SALE OF
SUBSTANTIALLY ALL OF THE ASSETS OF THE DEBTOR
What is the stalking bidding for if the asset shows no intellectual property a and no patent value is 0?
Is the stalking bid just a way to close the company process chapter 11? nobody will get a dime The bidder may not even pay the 2 million or 18 million. The filing shows no intellectual property. no intangible assets VALUE. or they are worth nothing on the assets.
The company put ZERO value on their patent and intellectual property even thought they spent over 100 million on it and received 2.6 million in license in 2023
The biggest creditor is Patheon who has $24,899,110.56 unsecured claim and is 'disputed'.
the second biggest lscs holding is a $4,769,205
Under bankruptcy, all the unsecured claims won't receive a dime.
The assets on the filing show not intellectual property or patent value so what is the stalking bid bidding for?
Liabilities:
40 million in liabilities: $40,976,106.13
30 million of the 40 million liabilities is disputed
Assets:
$486,736.89
shows no intellectual property assets on line 89
so what is the bidders bidding for? there is no Intellectual property or assets to bid ?
it's shows ZERO
Cash : $140,000 left in bank?
it had revenues of 2.6 million in licensing revenues. in 2023
I hope folks realize that this is trading on the Expert Market. Nobody can buy HGEN in the US. Only closing positions are permitted. The volume or price will not change much unless this comes off the Expert Market? At this point this is a Pure Lotto Play for the ones holding shares. Watching the Tic by Tic is a waste of one's time at this point. Let's see how the Bankruptcy Reorganization takes place and what's left? LOL
U should thank the failed management
"Well done!!" Thanks, shajandr.
Followers
|
326
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
43374
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators DTGoody cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |